BRAF and colorectal carcinoma: Among cases of receiving only chemotherapy CRC, the BRAF-mutant group exhibited a decreased progression-free survival (PFS) compared to the wild-type subgroup (median PFS: 6.97 months vs. 13.20 months; p = 0.064) (Figure 3F).